Evaluation of white opaque substance in gastric epithelial tumor detected after H. pylori eradication by administration of vonopraza
Not Applicable
- Conditions
- gastric epithelial tumor
- Registration Number
- JPRN-UMIN000032689
- Lead Sponsor
- Oita Red Cross Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients within 6 months from the day of eradication 2. Patients with antacid drugs before the first observation (within 7 days) 3. Patients with lesions with ulcers and bleeding which are difficult to observe the surface of the lesion 4. Patients with severe underlying disease 5. Patients with a history of gastrectomy 6. Patients who have complicated mental illness or psychiatric symptoms and seem to be difficult to participate in the study. 7. Other patients who are deemed inappropriate for the trial responsible physician or the test sharing doctor to conduct this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in tumor WOS expression (positive proportion) before and after Vonoprazan administration.
- Secondary Outcome Measures
Name Time Method Relationship between WOS expression and fasting gastric juice pH. Relationship between WOS expression and tumor histopathology (adenoma VS differentiation dominant VS undifferentiated dominant)